Healthcare provider profile · identity verified

Nancy Marie Denizard-Thompson, MD

Internal Medicine · WINSTON-SALEM, NC · NPI 1316043763

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	196	60
Amlodipine Besylate	Amlodipine Besylate	172	48
Gabapentin	Gabapentin	164	38
Omeprazole	Omeprazole	114	28
Fluticasone Propionate	Fluticasone Propionate	111	35
Albuterol Sulfate Hfa	Albuterol Sulfate	105	27
Ozempic	Semaglutide	94	16
Metformin Hcl Er	Metformin Hcl	92	25
Losartan Potassium	Losartan Potassium	89	25
Rosuvastatin Calcium	Rosuvastatin Calcium	87	27
Hydrochlorothiazide	Hydrochlorothiazide	77	21
Lisinopril	Lisinopril	72	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	65	suppressed
Diclofenac Sodium	Diclofenac Sodium	64	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	62	13
Levothyroxine Sodium	Levothyroxine Sodium	58	13
Metformin Hcl	Metformin Hcl	58	18
Metoprolol Succinate	Metoprolol Succinate	49	14
Trazodone Hcl	Trazodone Hcl	45	suppressed
Jardiance	Empagliflozin	40	suppressed
Mounjaro	Tirzepatide	39	suppressed
Tramadol Hcl	Tramadol Hcl	34	suppressed
Carvedilol	Carvedilol	31	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	31	suppressed
Potassium Chloride	Potassium Chloride	31	suppressed
Eliquis	Apixaban	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Allopurinol	Allopurinol	29	suppressed
Furosemide	Furosemide	28	11
Nystatin	Nystatin	28	suppressed
Symbicort	Budesonide/Formoterol Fumarate	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Trulicity	Dulaglutide	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Spironolactone	Spironolactone	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Famotidine	Famotidine	19	suppressed
Lidocaine	Lidocaine	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Labetalol Hcl	Labetalol Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Colchicine	Colchicine	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Baclofen	Baclofen	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Simvastatin	Simvastatin	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Atenolol	Atenolol	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Humalog	Insulin Lispro	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	11	11
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error